SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " trial " 1,387 found 🔀 AI-powered Shuffle
How burnt coconut helped discover new to science endemic species in Sri Lanka
COLOMBO — As dusk settled over the paddy fields at Puwakpitiya, a village on the northern edge of Knuckles Mountain Range locally known as Dumbara mountains in Central Sri Lanka, researchers began laying traps along the uneasy boundary between farmland and forest. They were targeting small terrestrial mammals moving through the landscape. On the ground, […]
Lindsay Clancy mistrial leaves criminal justice students divided over mental health concerns
The Voice of the Seton Hall Community.
The politics and possibilities of ‘AI could kill us all’
I found myself fielding a lot of questions from folks who don’t usually talk much about AI this week. They were mostly along the lines of “do you think AI is going to kill us all?” or “how worried should I be about this human extinction stuff?” Motivating this wave of existential anxiety was the highly dramatic resignation of now-former Anthropic employee Jacob Coxon, who quit his job while publicly sharing his concerns about safety practices at the leading AI companies. More specifically, he declared that almost everyone at OpenAI and Anthropic, the leading AI labs, believes that there’s a decent chance the AI systems they’re producing could “kill us all” by the end of the decade, and the companies aren’t “acting responsibly.” Other AI safety researchers, including those still employed at Anthropic and OpenAI, all confirmed that yes, Coxon is correct, they’re all worried that their company’s products might prove fatal for the entire human race as well. Two more AI employees quit and joined the chorus. Now, the warning shot has been covered everywhere from the Wall Street Journal to Fox News to WIRED to the Guardian. I understand why all this sounds scary, but my response to those who have asked, has generally been: No, you don’t need to worry that AI will kill go rogue and kill us all. But that does not mean we shouldn’t worry, period. Far from it. The companies building AI products are now among the wealthiest and most powerful entities in the world. And they very much are building enormous engines of mass surveillance, extraction, and automation. They can and have allowed their AI systems to carry out felony hacks of other companies, provided the government with autonomously generated kill lists, and sold enterprise technology to firms around the world that is explicitly intended to replace jobs. But “AI” has done these things not because they have all-powerful minds of their own but, ultimately, because people have programmed, calibrated, and directed them to. In other words, it’s not AI we need to worry the most about. It’s the people and corporations working to profit from and gain power by deploying it. The technology is sophisticated, sure, and, especially in cybersecurity contexts, potentially disruptive to plenty of existing systems. But if we want to stop this predatory, profiteering, and extractive form of AI—and it’s worth noting that at this point, most people do—we absolutely can. A quick note/plea: I can only do all of this with the support of readers like you, so if you find value in independent, critical tech journalism and analysis, please consider becoming a paid subscriber. I want to keep as much of this un-paywalled as absolutely possible, and I need your support to do so. Many thanks to all who continue to chip in, it’s very much appreciated. Onward. Subscribe First, some context: AI industry folks like Coxon have been discussing the prospect that AI will destroy humanity for years. Even before the beginning of the AI boom, many working in the industry, from the executive staff to the rank and file researchers, have obsessed over ‘x-risk’, or the possibility that AI will become sentient or semi-sentient and move one way or another to exterminate humanity. This is ostensibly why Elon Musk bankrolled OpenAI in the first place, and is the grounds for his lawsuit alleging OpenAI betrayed its charter by abandoning its nonprofit status to become a commercial enterprise. Many AI engineers and startup founders have calculated their own personal p(doom), or the probability that the tech product they are working on will initiate an actual humanity-extinguishing apocalypse. 10-25% p(doom)s are pretty common. (I wrote about a long weekend I spent among these folks at one of their top conferences here, to give you an idea of their ideas and belief systems.) Sam Altman himself drove the narrative of the imminent rise of a super-powerful AI, or artificial general intelligence, to prominence by declaring that the technology he was building posed an existential risk to humanity. This idea is in other words baked into the DNA of modern AI companies and into the products they engineer. It’s also why the industry is routinely accused, by myself and others, of “doom marketing,” ie, using such proclamations and framings to impart the sheer power of the technology behind your product onto investors, partners, consumers, and the state. Some ambient understanding of this tendency may have helped prevent the press from repeating the claim every time one of the x-risk folks made it over the years, including when they quit their jobs at AI companies while doing so. Yet Coxon’s AI x-risk alarm has broken containment, as they say, and has exposed the idea to the mainstream media once again. This has happened, I think, for a number of reasons. First, when AI CEOs were going around saying AI might kill everyone in 2023, their companies were well-capitalized, but not nearly to the extent they are today. They were more easily dismissed as eccentric geeks of the sort that Silicon Valley is supposed to produce. Now, not only do their products have much greater market saturation, but people are more aware of a) the often unethical ways the executives and companies comport themselves b) the other adverse impacts of AI that have already arrived, and c) the physical cost of building these systems, particularly when it comes to data centers. Finally, toss in the constant stream of headlines in 2026 about AI models going rogue or potentially upending the world’s infrastructure. [ ](https://www.bloodinthemachine.com/p/with-the-backlash-to-data-centers) [ With the backlash to data centers, Flock and AI glasses, a mass opposition to big tech is underway. Silicon Valley is in denial. ](https://www.bloodinthemachine.com/p/with-the-backlash-to-data-centers) Brian Merchant · Aug 27 [ Read full story ](https://www.bloodinthemachine.com/p/with-the-backlash-to-data-centers) As a result, general sentiment was already overwhelmingly skeptical of AI and its overlords, so the table was pretty well set for someone to come along and say ‘just a reminder, the companies that are building the product that promises to take your job and leave a data center in your neighborhood also think that it might exterminate the human race’ and get a strong reaction from the media and the public. The question is: Should we understand this stuff as hype, strategically fanned to feed already swelling valuations? Is it doom marketing? Genuine cause for alarm that the infrastructure that undergirds modern life is facing a novel threat vector? Or reason to be sincerely worried that AI companies are amassing too much power, and that their products are genuinely dangerous? The answer, I’m afraid, is “yes.” Let me try to untangle all of this a bit, because arguments over how to navigate this moment are extremely heated right now, as they are essentially arguments over how to approach the politics of AI at a moment where there may be a unique opening for action. Those sympathetic to AI alignment concerns and x risk arguments—which increasingly includes a faction on the left who want to shut down AI over safety concerns—argue that people who dismiss AI as all hype have their heads in the sand. Meanwhile, critics of the x-risk narrative—which I might note includes a cadre of investors and tech folks on the right, too—argue that it is hype and can be used to further inflate valuations or for pursuing regulatory capture. The challenge is that many feel that dismissing AI as just hype or purely marketing also diminishes the urgency of taking on the AI industry as the novel and threat to labor, civil society, and the public sphere it is; others that by accepting the industry’s own terms, we imbue it with undue power and enable it. But let’s be clear: Declarations that AI is so powerful it might end the world are a kind of marketing, and anyone who says otherwise is just as off base as those who say that’s all that it is. If you don’t think that these sub-trillion dollar companies have higher-ups who noticed that when their founders talked about super-powerful dangerous AI they got spikes in media interest and phone calls from investors, or that those founders didn’t notice that themselves, and lean into certain narratives to advantage their products, then I don’t know what to tell you. Not all marketing is a Pepsi ad campaign with a celebrity spokesperson. Yet confronting the AI industry should certainly be considered an urgent project. Do I share the x-riskers’ fear that out-of-control, super-intelligent AI agents might end the world? I do not. I’ve read a good deal of AI extinction literature over the last couple of years and I have not come across a credible, step-by-step documentation of how exactly AI might move from self-recursively improving AI to killing every single human on the planet. Most of what I’ve read seems predicated on a sort of reverse Ian Malcolmian logic: Eventually, it becomes smart enough and AI, uh, finds a way (to exterminate humanity). Are the AI companies also overstating and dramatizing what their products can do? Yes, pretty much all the time. They’re in a knife fight for market share and are trying to win customers and government contracts before their investors come knocking. And yet. They have concentrated enormous amounts of compute, have extensive data collection and surveillance capacities, have inserted themselves into the state in numerous capacities, including military kill chains, and they are being run by egomaniacal billionaires who are rushing to monopolize an entire new market. The way I think about their most recent frightening-seeming exploits is not as a “swarm of rogue AI agents building a new civilization” or whatever, but as corporations with a hitherto-unimaginable amount of compute at their disposal recklessly experimenting with automation programs, completely unafraid of any repercussions because we have been unwilling or unable to impose any on them. So I think we should welcome any newfound imperative to hold them accountable. I also think that ultimately, the AI critics, Pause AI folks, leftists, doomers, effective altruists, and, honestly, most of the public, want a lot of the same things: legitimate checks and limits on AI companies’ power, actual transparency into what the companies are doing, and for more of AI to be under public control. (Ultimately, a lot of what animates the x-risk fears are rooted in just that: a fear of losing control.) How we move towards all this, exactly, is the question of the day, and while there’s much to be argued over in terms of building a viable political platform to challenge the AI industry’s power, I do want to cast a vote against one particular approach. Not to pick on Chris here, as there are a lot of folks out there proposing stuff like this, and the policy ideas actually stem from AI safety groups. But not only would this be challenging to land politically (I can already hear the ‘China will beat us to AGI’ calls) and all but unworkable in practice, this approach is a) far too limiting, b) fails to address the current harms caused by AI and c) would likely only wind up serving Anthropic and OpenAI; it’s what regulatory capture looks like in action. Full model transparency is the floor for what should be on offer here. If these companies believe their products will kill us, the very least we deserve is to know how. It’s in the public interest. I would also argue we might get a lot of the way to stopping any currently envisioned robot apocalypse simply by forcing AI companies to assume liability, and to submit to the full brunt of the law. If Sam Altman were liable to be charged with a felony for approving the hack on Hugging Face1, if Google was forced to pay defamation fines each time it published a false and injurious AI Overviews, these companies might suddenly find cause to restrain their models’ output, and we might hear less about rogue AI. We would need to introduce new frameworks and available tools for tracking automated lawbreaking, to be sure, but I’d wager that little would frighten the AI companies more than actually being held accountable for what their products enable. To that end, Illinois has passed an AI liability law, which the industry fought tooth and nail, and Florida is considering one. The next steps would be towards moving AI under public control; again, it’s only reasonable, since everyone, not just AI insiders, should get a say over how a technology whose developers say might kill us is developed and deployed. Dismantling the whole industrial project as currently structured should be on the table, too, pending democratic input. But that’s for another post. For now, suffice to say that while I won’t be losing any sleep about an AI-enabled extinction event, Mr. Coxon and co. have given us an opportunity to underscore the urgency of the clear and present damage AI companies are doing, the extreme power they wield and the extent to which they hold themselves unaccountable, and the abundance of political capital there is out there for taking them on. Subscribe 1 Purely speculative! I do not know if he did or not.
India Wants to Buy Fewer Chinese Imports, but Keeps Needing More
Trade between India and China has nearly doubled in five years, leaving New Delhi with a widening deficit and a difficult choice over how to build its industrial future.
Rapper Lil Durk acquitted of murder-for-hire at Los Angeles trial
A federal jury has found rapper Lil Durk not guilty of attempted murder for hire of rival rapper Quando Rondo.
Rapper Lil Durk acquitted of murder-for-hire at Los Angeles trial
A federal jury has found rapper Lil Durk not guilty of attempted murder for hire of rival rapper Quando Rondo | WWL
Grammy-winning rapper Lil Durk found not guilty in murder-for-hire trial
Lil Durk, the Grammy-winning rapper born Durk Banks, has been acquitted on all charges in a federal murder-for-hire case in Los Angeles.
Posts touting mebendazole as cancer treatment go beyond the science
The anti-parasitic drug mebendazole has shown preclinical efficacy in targeting multiple cancers, but experts say social media posts calling it a "cure" go too far. Additional clinical trials in humans are necessary to prove when, at what dosage, and in which treatment combinations it could make an impact.
Posts touting mebendazole as cancer treatment go beyond the science
The anti-parasitic drug mebendazole has shown preclinical efficacy in targeting multiple cancers, but experts say social media posts calling it a "cure" go too far. Additional clinical trials in human...
The dirtiest places on an airplane; testing for a breast cancer gene mutation; the evolution of esophageal cancer; plus other stories with Vanderbilt Health sources
William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: WKRN News 2 (heat-related illness); NBC News (how bad will flu and COVID be this winter?); AAA’s The Extra Mile (the dirtiest places on an airplane); WKRN News 2 (again) (measles in Tennessee); and The Tennessean and Healthline (new COVID vaccines). Schaffner also spoke to the EMJ European Medical Journal for a Q&A interview. Tuya Pal, MD, Professor of Medicine, was quoted in a New York Times story about testing for a breast cancer gene mutation. Michael Gibson, MD, PhD, Professor of Medicine, was quoted in a MedPage Today story about the epidemiologic evolution of esophageal cancer. Medpage Today writer Shannon Fritz quoted Shravani Durbhakula, MD, Associate Professor of Pain Medicine, who answered questions about a street drug called cychlorphine. Becker’s Behavioral Health picked up the story. WSMV Channel 4 News reporter Diana Rocco interviewed Michael Caucci, MD, Associate Professor of Psychiatry and Obstetrics and Gynecology, for a story about postpartum psychosis and the trial of Lindsay Clancy.
Greenbrier Commerce Center Adds 262,880 Square Feet Of Industrial Space
Colliers | Alabama will serve as the exclusive landlord representative for Greenbrier Commerce Center, a 262,880-square-foot Class A industrial development
Iowa communities grapple with regulating data centers as development spreads
As data center development spreads across to Iowa, at least six cities and 10 counties are considering policies to regulate the industrial use. Several local governments have enacted moratoriums, ranging from three months to 18 months, as officials draft ordinances to govern the developments and their impact on resources while also allowing for economic growth. …
The core arguments behind the Rockstar union busting trial
Both parties have set out their stall in legal documents obtained by Game Developer.
Everyone hates data centers. Lawyers love them
Jason Morris spent years helping housing, office and industrial developers cut through red tape and NIMBYs around Phoenix. Occasionally, the land-use attorney advised data center builders.
"Hiring Shouldn't Take Months": MCE Staffing Unveils On-Demand Staffing Solution for Growing Businesses
LONDON, UK / ACCESS Newswire / September 11, 2026 / , a UK-based recruitment and workforce solutions provider, today announced the launch of its on-demand staffing solution, designed to help businesses fill roles in days rather than weeks or months. The new service is aimed at companies across industrial, warehousing, hospitality, and commercial sectors that need to scale their workforce quickly without sacrificing quality of hire.
Translating the Open Digital Ecosystem Principles to Business Transformation Strategy
ARC Advisory Group’s Open Digital Ecosystem Working Group outlines how open, governed, interoperable data foundations can support scalable digital twins, industrial AI, and measurable business transformation.
Fyffe gets state grant to prepare industrial park for new business
Fyffe received more than $40,000 through a state grant to help prepare its industrial park site for businesses looking to move in.
Former crypto billionaire Sam Bankman-Fried appeals conviction to Supreme Court
Sam Bankman-Fried, the former crypto mogul who was convicted of defrauding investors by secretly diverting billions of dollars of their money, asked the Supreme Court on Thursday for a new trial and to throw out a court order requiring him to pay $11 billion as part of his sentence.
In Good Health: The Matter Of Maternal Mental Health Care
The Lindsay Clancy murder trial captivated the American public for weeks.Prosecutors charged Clancy with murdering her three children. They say she then tried to take her own life and that her injuries left her paralyzed from the waist down. Clancy’s lawyers say she was experiencing postpartum psychosis and should not be held criminally responsible. But prosecutors say she planned the deaths.After seven days of deliberation, the jury remained deadlocked and the case ended in a mistrial.The trial has divided the nation and sparked conversations over about maternal mental health, raising questions over gaps in care for parents after giving birth. About one in five expecting or postpartum women in the U.S. experience mental health disorders. And according to a 2025 study, overall maternal mental health has dramatically dropped in the past seven years, with only 25 percent of moms reporting excellent mental health.What do we know – and don’t know – about maternal mental health care? And how can our systems be bolstered to help those who need it most after giving birth?If you are experiencing a mental health crisis or thinking of harming yourself, the 988 Suicide and Crisis Lifeline is available 24/7 by phone and text. The National Maternal Mental Health Hotline is also available 24/7. You can text, call or chat at 1-833-TLC-MAMA. The Postpartum Support International also offers a helpline at 1-800-944-4773 or you can visit postpartum.net.Find more of our programs online. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.
Gulf South Commerce Park begins work on first industrial warehouse, acquires more acreage
Developers of an industrial business park near Mandeville are constructing the first warehouse on the property, and recently acquired more acreage.
Charlie Kirk’s legacy, political violence & case against Tyler Robinson: One year later
One year after Charlie Kirk’s killing, Turning Point USA is growing as the man accused of his murder prepares to stand trial.
Tunisia: Authorities must immediately release Rached Ghannouchi amid severe fair trial violations and serious health concerns
Tunisian authorities must release prominent opposition politician Rached Ghannouchi, quash his convictions and end the politically motivated prosecutions against him marred by significant due process violations, Amnesty International said today. The organization is also urgently calling for him to receive access to adequate healthcare pending his release. The 84-year-old leader of the Ennahdha party and former Speaker of Parliament has been held in arbitrary detention since his arrest in April […]
August was world's joint-hottest month on record, scientists say
The world just experienced its joint-hottest month since records began, with August pushing the planet's average global temperature to more than 1.5 degrees Celsius (2.7 degrees Fahrenheit) above pre-industrial levels, the EU's Copernicus Climate Change Service (C3S) said on Thursday.
NMSU FIRE Venture Fellow completes summer internship with El Paso health innovation startup
Grace Valentine Olagunju, a New Mexico State University graduate student and member of the 2026 Fourth Industrial Revolution Economy Venture Fellows cohort, has completed a summer internship with...
China slams US claims of ‘industrial-scale’ AI theft
The response comes after three US agencies accused Chinese AI companies of exploiting American AI models.
Héctor Socas, astrophysicist: ‘If a more advanced civilization contacted us, they should be more afraid of us than we are of them’
Artificial intelligence, extraterrestrial life, the climate crisis, the future of work and global governance. This science communicator uses the lens of science to tackle a much broader question: what kind of civilization do we want to be?
Electrical Trade Attracts New Workers; Small Business Optimism Dips in August
WARREN, Ohio – Women are finding a growing place in the electrical trades, with apprenticeship programs in the Mahoning Valley reporting increased interest and enrollment. Young apprentices are gaining experience across residential, commercial and industrial work while preparing for careers in the field.
Prologis bets on Chicago-area warehouse demand with $100M Minooka project
The move by the nation’s largest owner of industrial real estate is a notable sign that developers and lenders are growing more confident about speculative warehouses after pulling back in recent years.
Seneca adds new women's health service
Seneca Healthcare District announces the addition of endometrial ablation to its women's health service line at the Lake Almanor Clinic, providing local
Sleepy Hollow boiler business sues CT competitor
A Sleepy Hollow industrial boiler business claims that a former employee and a competitor have taken its trade secrets. Miller
Mental health care before, after surgery improves recovery in older adults
A WashU Medicine clinical trial supports adding mental health coaching and medication cleanup to routine pre-surgical care.
Health-ISAC warns ShinyHunters targets health sector with vishing, credential theft and MFA bypass tactics
Health-ISAC alert warns ShinyHunters targets health sector with vishing, credential theft and MFA bypass tactics.
Council leans toward denying Springfield behavioral health campus annexation
Councillors did not vote on the annexation at the meeting but considered whether the planned crisis stabilization center and behavioral health hospital are consistent with the city’s plans for the area, which is designated for light industrial uses.
Epic v. Health Gorilla: “Working as Designed”
We’ve been on a bit of a legal bender since just before Labor Day, so let’s keep a good thing going! As predicted, Epic does not want its case against Health Gorilla consolidated with the data breach cases, so it filed a motion to vacate the conditional transfer. And because they had to explain to the Panel why this case is different, they put a good chunk of previously unseen Epic v. Health Gorilla discovery record on the public docket! Roll the tape! The Case Against Consolidation Before we get to the fun stuff, let’s do the housekeeping. Epic's motion boils down to three arguments (sorted in ascending order of how well they land): A judge has already decided this. Judge Olguin declined to relate the fraud action to another ELU case (Patterson v. UVA Health), holding that the two do not call for determination of substantially similar questions of law or fact. Epic asks the Panel to treat that (a Rule 42 ruling) as law of the case. The overlap is thin. The three common questions Health Gorilla and the Panel identified are neither numerous nor complex (the qualities the Panel looks for before centralizing). Moreover, they are outnumbered by the questions unique to each side: The breach cases turn on security architecture, notification timing, and patient-level access. The fraud action turns on false treatment attestations and breaches of the framework agreements. Consolidation costs more than it saves. 17 of 21 parties in the fraud action do not appear in a breach case. The cases are also at very different stages: Olguin has a scheduling order running through a January 2028 trial while the breach actions are much more nascent. I like the last two more than the first because they attack the basic economics of an MDL: there just may not be enough shared discovery here to justify dragging all the defendants and a relatively mature fraud case all the way to Florida. On the other hand (while I know exceedingly little about MDL and Rule 42), I have a hard time seeing why a district judge's decision about his own docket would control what the Panel does with the separate § 1407 question. I might be reading between the lines too much, but I sorta think Epic's own brief half-concedes this, framing the two provisions as "two sides of the same coin" but then adding "respectfully submit" (which is often lawyer speak for “we know this is a reach”). The Ladder Gets More Rungs Anyway, the arguments are not why you're here (aside from the lawyers, maybe). Back in June, we discussed how Epic was using the smaller defendants to build an evidentiary ladder toward Health Gorilla and Unit 387. Turns out discovery has been adding a few rungs of its own.
September 9, 2026: Embedded Trials in a Learning Health System, in This Week's Rethinking Clinical Trials Grand Rounds
In this Friday’s Rethinking Clinical Trials Grand Rounds, Ryan Zarychanski of the University of Manitoba will present “Embedded Trials in a Learning Health System: A Hospital Policy of Tranexamic Acid […]
Lindsay Clancy and postpartum psychosis
The trial around Lindsay Clancy may be over for now, but it still leaves us with questions. On today’s episode, we talk to psychiatrists and patients to answer them: What is postpartum psychosis, exactly? Why don’t we know more about it? And what can you do if you are worried about a postpartum loved one?Interested in more stories on mental health? Email us your question at shortwave@npr.org.Support public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org.
Traditional Inuit Diet: Foods, Nutrition, and Health Effects
Traditional Inuit diets combine nutrient-dense marine and terrestrial country foods that remain important sources of protein, vitamin D, vitamin B12, iron, and other essential nutrients. The transition toward market foods is occurring alongside changes in cardiometabolic health, micronutrient intake, and gut microbiome patterns, while food insecurity, socioeconomic conditions, physical activity, colonial processes, and environmental change complicate the relationship between diet and health.
Have we found alien life? Hundreds of scientists weigh in
Two major alien-life announcements in 2025 generated enormous excitement, but most astrobiologists remained unconvinced. Only 6.6% of surveyed experts thought possible biological molecules on K2-18b probably represented extraterrestrial life, while 15.1% said the same about intriguing mineral patterns in a Martian rock.
Chinese scientists find a hidden atomic structure that unlocks methane
Scientists found that a tiny atomic structure that forms on nickel oxide during methane conversion is more effective than the metallic nickel long believed to drive the reaction. The discovery allowed a low-nickel catalyst to rival one containing 10 times more metal, potentially opening the door to cheaper and more efficient industrial catalysts.
New business park latest in Painesville’s mounting development
After years of bringing new housing and entertainment options to the Lake County city, moves are now underway to clear the way for industrial and commercial uses.
Drug developed for lung disease may slow biological aging in surprising ‘bonus’
Rentosertib, an AI-discovered drug for idiopathic pulmonary fibrosis, made patients appear three to four years biologically younger in a clinical trial.
Microbiome transplants may curb food allergies
Gut microbe transplants treated some peanut allergies in an early-stage clinical trial.
No Evidence That Sugar Substitutes Harm Weight, Health, or Sweet Taste Preferences
New review of three major EU-funded trials shows swapping sugar for non-nutritive sweeteners may help with weight loss maintenance, while broader "sweet taste" exposure appears largely neutral for health.
Louisiana concrete companies join forces to capitalize on construction boom
Two Louisiana concrete suppliers are joining forces with two out-of-state companies to pursue large-scale construction projects as billions of dollars in new industrial and technology investment move … Already an INSIDER? Sign in. Already an INSIDER? Sign in
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
Oil prices keep rising and weigh on Wall Street
U.S. stocks are drifting lower in their return to trading following a three-day weekend. The S&P 500 dipped 0.2% Tuesday. The Dow Jones Industrial Average fell 477 points, and the
DeWitt’s Crossroads Business Park gets ready for growth
DEWITT, Iowa – Community leaders and development partners recently celebrated the groundbreaking of five regional water detention ponds in an expansion of the Crossroads Business Park, marking a major milestone in preparing the site for future industrial growth. The project is the first phase of infrastructure improvements that will make approximately 125 acres of development […]
Why Life’s Origin Can Only Be Explained by Design
The reagents of the feedstock are never produced by processes as on the early Earth. Production requires substantial energy and controlled industrial procedures
Sinclair's Criminally Obsessed to Present "Maternal Mental Health: How the Lindsay Clancy Trial Could Change Treatment" National Town Hall to Air on September 9
BALTIMORE – September 8, 2026 – Sinclair today announced a national town hall examining maternal mental health and the questions surrounding diagnosis, treatment and intervention that have been brought into focus by the Lindsay Clancy trial. Maternal Mental Health: How the Lindsay Clancy Trial Could Change Treatment will stream September 9 across Sinclair’s television station...
Eureka Springs Police Chief creates unique system for enforcing the rules of the permanent entertainment district trial
To make understanding this trial easier, Eureka Springs Police Chief Billy Floyd set up a patrol checklist to track disturbances and how many times they’ve had to remind people of the rules.
Eureka Springs Police Chief creates unique system for enforcing the rules of the permanent entertainment district trial
KY3's Billie Brightman reports.
Huawei heads to trial in US over its business dealings in Iran
Eight years after U.S. prosecutors secretly charged China's Huawei Technologies with defrauding HSBC and other banks over its business with Iran, the case is finally heading for trial.
Huawei Heads to Trial in US Over Its Business Dealings in Iran
By Karen Freifeld NEW YORK, Sept 8 (Reuters) - Eight years after U.S. prosecutors secretly charged China's Huawei Technologies with defrauding HSBC and other banks over its business with Iran, the case is finally heading for trial. Huawei also faces charges for conspiring to steal trade secrets ...
Ebola outbreak outpaces containment despite influx of money and supplies
Although the U.S. has allocated hundreds of millions of dollars and vaccine trials are underway, Ebola deaths continue to climb in the Democratic Republic of the Congo.
Cyberattacks on food and agriculture can turn disruptions into safety crises, threatening public health and supply chains
Cyberattacks on food and agriculture can turn disruptions into safety crises, threatening public health and supply chains
We can’t afford to learn the wrong lesson from the Lindsay Clancy trial
"Better coordination may not prevent every tragedy, but in high-risk care it is essential," writes Lauren Hajjar. "A collection of services is not the same as a system of care, and a person in crisis should not be responsible for connecting the pieces."
Perilla frutescens Benefits: Effects on Allergy, Inflammation, Immunity, and Gut Health
Perilla frutescens contains phenolic acids, flavonoids, and other bioactive compounds that show anti-allergic, immunomodulatory, anti-inflammatory, and gut-protective effects across laboratory and animal studies. Limited human evidence, including a small randomized trial of rosmarinic-acid-enriched Perilla extract for seasonal allergic rhinoconjunctivitis, is promising, but larger standardized clinical trials are needed.
Clancy murder case spotlights maternal mental health in U.S., Arkansas
The murder trial of Lindsay Clancy in the January 2023 killing of her three young children ended in a mistrial in Massachusetts on Friday when one of 12 jurors refused to join the others in finding her not guilty by reason of insanity.
Tate & Lyle strengthens climate ambition with updated science-based targets to reduce greenhouse gas emissions
Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, announced updated science-based targets to reduce greenhouse gas emissions (GHG) across its operations and supply chain. The new targets, which have been validated by the Science Based Targets initiative (SBTi) as consistent with reductions required to limit global warming to 1.5°C above pre-industrial levels, apply to Tate & Lyle’s expanded global footprint and supply chain following i...
The war on Iran’s energy infrastructure creates rising political risk
When Israel targeted Tehran’s oil storage facilities in the initial days of the war launched on Feb. 28, black smoke blanketed the capital and plunged parts of the city into darkness. Roughly ten days later, strikes hit natural gas facilities at the giant South Pars field, key oil refineries, major steel plants, and petrochemical complexes, impacting thousands of workers. These attacks on vital energy and industrial assets revealed a critical dimension of the conflict: compounding an already acute domestic energy...
Scientists covered 200 square metres of a Swiss glacier with sheep’s wool; early tests found it protected the ice about as well as plastic sheets, but only 0.02% of Swiss glacier ice is covered
A natural wool covering placed over 200 square metres of high-altitude Alpine ice has proved as effective at slowing summer melting as conventional synthetic tarpaulins, offering a possible biodegradable alternative to plastic sheets. Initial results from the "Keep It Wool" trial on the Tsanfleuron Glacier in western Switzerland show that prototype wool blankets protected snow and ice from heat about as well as plastic geotextiles.
Lindsay Clancy trial sparks mental health debate
In the aftermath of Lindsay Clancy's murder trial, clinical psychologists are calling for more awareness around rare postpartum conditions. Reporter Deborah Valentine has more.
Key moments in the Lindsay Clancy case: the 911 call, mental health care, mistrial
The judge has declared a mistrial in the Lindsay Clancy murder trial. After seven days of deliberating, the jurors failed to reach a verdict on whether she was criminally responsible for killing her three young children at her Massachusetts home. Judge William Sullivan declared the mistrial Friday. That came after jurors sent a note saying that they were “unable to come to a unanimous decision and will not be able to." The emotionally charged case has sharply divided many Americans and generated intense interest for over a month. It’s drawn attention to issues around maternal mental health after childbirth.
Hiltzik: High-tech bros go from the pedestal to the dock
Familiarity ultimately breeds public contempt for technology pioneers
Inside the business of finding expert witnesses for major trials
In high-stakes trials, the outcome can hinge on who takes the stand as an expert witness — and one of the most experienced companies in finding and supplying...
The science behind the beauty business
Some of Europe’s industrial champions may be in retreat, but its cosmetics sector remains a global leader, buoyed by healthy demand, recognised brands and a reputation for innovation."The fact is, the science in cosmetics is better here in Europe than anywhere else in the world,” says Pierre Morvan, CEO of Technature, a private label cosmetics manufacturer located near Brest in France’s northwestern Brittany region. “You have to have good science in order to make the difference, and that is why we invest so much in research and innovation.”Across Europe, the beauty and skincare products sector supports an estimated 3.6 million jobs, including 265,000 employed directly in the industry, according to the Cosmetics Europe trade group.. Cosmetics production contributes an estimated €11 billion to the EU economy, and generated €30 billion in export revenue last year, a €400 million rise from 2024.Technature itself has a global footprint, supplying products for 1,500 brands in 65 countries. Its range of skin gels, facial masks, nail treatments and other products include natural ingredients and extracts derived from plants, such as seaweed, that are developed and refined through science-based analysis and testing.While industry projections point to sustained growth for the foreseeable future, driven by emerging economies and wider availability of exclusive brands that were once chiefly sold by high street retailers, the sector is not immune to the impact of geopolitics and trade wars. The Trump Administration’s tariff threats have dented cosmetics exports to the EU industry's largest overseas market. After the European Parliament approved the EU-US Turnberry Agreement in June, setting a 15% levy on many EU goods, the French Federation of Beauty Companies warned that “exports are falling sharply” and urged the EU to negotiate an opt-out for cosmetics.Technature’s CEO flags South Korea as an emerging competitor, partly due to its assertive marketing efforts. “I would have to say I am a little bit scared,” Morvan says, regarding the growth potential of the South Korean cosmetics industry. “This is why science and innovation are so important if Europe is to remain the leader.”With a workforce of 200, including biologists, chemists and other scientists, around 15% of Technature’s staff work in three research and development (R&D) labs. A similar number work in four quality control and assurance facilities, where science plays a crucial in ensuring product safety in a sector that is subject to the European Cosmetics Regulation.Educational exchange between industry and academiaIn recognition of Technature’s research and innovation, Morvan was selected as one of Brest’s ambassadors to Science Comes to Town (SCTT), a European initiative to strengthen communications and understanding between science and society. Brest is one of three coastal cities in the EU-funded programme, alongside Split (in Croatia) and Kiel (in Germany). From 7-11 September, Brest will host the EU TalentOn contest featuring 100 early-career researchers from across Europe.Morvan appreciates the value of engagement with educational and scientific institutions as well as the home community. For instance, Technature collaborates closely with university partners to enhance its in-house R&D. In addition, it invites students to its labs and sends its own researchers to local institutions. "We absolutely want the students to know what the industry is all about,” Morvan says, noting that seeing science in action can help young people “understand that they can do something real with science, to create something with what they are learning.” He says another important benefit: encouraging new generations of young people to consider a career in cosmetics.Community involvement also raises awareness about Technature and the skincare industry as a whole. “The public gains recognition of the innovative company that we are, and this is important for getting new customers,” Morvan says. One of its recent innovations — tiny, colourful cosmetic pearls that release skin moisturisers on application — was showcased at this year’s VivaTech event in Paris.Morvan holds a master's degree from the Brest Business School and studied animal production and biology in Brest at the University of Western Brittany (UBO), an SCTT partner, and at the University of Tours. He got his start in business in 2002, initially working on using seaweed as a raw material in the food industry before transitioning to cosmetics. Morvan has always been interested in connecting science and business, reflecting one the goals of SCTT to enhance public-private collaboration.The invitation to participate in SCTT was unexpected. “It was a surprise to get a call from the city of Brest saying that they wanted me on this programme,” Morvan recalls, adding that officials were drawn by his company’s R&D. “It's not only theory and science fundamentals. Our science is something that is applicable to the global market — and important for the community.”Science|Business, which connects policymakers, academics and industry through its news reporting, analysis and events, is an SCTT partner.
Judge to allow discussion of woman’s mental health history in ex-officer’s murder trial
In a matter of weeks, a former Stoughton officer is set to go on trial for the murder of a 23-year-old Canton woman and her unborn child.
How to Watch Big Brother Season 28, Episode 30
Watch Big Brother live with TV channel, start time and streaming info. Stream Season 28, Episode 30 on Fubo — no cable required, free trial available.
Merrimack Anheuser-Busch Property purchased by United Therapeutics Corporation
Biotechnology firm United Therapeutics Corporation has acquired the former Anheuser-Busch brewery site in Merrimack for $47 million, according to sources familiar with the matter. The transaction secures one of Southern New Hampshire’s largest industrial parcels, spanning nearly 300 acres off Daniel Webster Highway
Signant Health, Lothar Medical Plan Integrated Respiratory Trial Device
Signant Health and Lothar Medical plan integrated respiratory trial device combining spirometry, oscillometry, and FeNO measurement into a single platform.
China mines iron from tailings and low-grade ore to cut Australia, Brazil supply
Scientists have found a way to turn waste into a valuable resource on an industrial scale, reducing China’s dependence on iron ore imports.
Video Pediatrician on postpartum mental health
With the Lindsay Clancy murder case ending in a mistrial, ABC News' Dr. Alok Patel discusses postpartum health and checking in on parents with newborns.
Firefighters respond to business fire in north Jefferson County
Louis Allis is a manufacturer of electric motors and related industrial equipment.
Firefighters respond to business fire in Blount County
Louis Allis is a manufacturer of electric motors and related industrial equipment.
Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials
Signant Health, a leading provider of evidence generation solutions for clinical trials, and Lothar Medical today announced that they have signed a letter of intent outlining a planned strategic collaboration to bring Lothar Medical's next-generation pulmonary function technology to the global clinical trial market.
Apollo’s €3bn Bayer deal shows ‘non-control’ financing is spreading to operators
Apollo’s €3bn Bayer LARC investment and a $35bn Broadcom financing highlight how private credit is funding AI and industrial capex without operators giving up c
Lindsay Clancy murder trial has divided US on whether she's victim or criminal
Some say the case shed light on the mental health struggles of mothers, while others argue it's no excuse for murder.
Is There Alien Debris on the Moon? Some Scientists Plan to Find Out.
Researchers want to explore the idea that microscopic particles shed by alien civilizations have accumulated on the lunar surface, making it an archive of extraterrestrial technology.
‘There is light at the end of this tunnel. But the tunnel is filled with sewage’: Marina Hyde on finding hope in political chaos
The Guardian columnist reflects on how she stays upbeat in a chaotic age of ejector-seat prime ministers, Mars-bound baddies and at least one celebrity ski-massacre trial …
Las Vegas defense attorney says Lindsay Clancy mistrial points to mental health defense strength
With the Lindsay Clancy murder trial ending in a mistrial, a prominent attorney breaks down why the 11-1 deadlock in favor of insanity is a win for the defense.
Experts explain postpartum mental health amid Lindsay Clancy trial
Struggling with mental health after giving birth is fairly common. Support and awareness are key to helping new mothers.
OB-GYN on maternal mental health after mistrial declared in Lindsay Clancy case
Dr. La Tanya Hines, an OB-GYN with Kaiser Permanente, discusses postpartum psychosis and postpartum depression. This video was broadcast during the NBC4 News at 4 p.m. on Friday, Sept. 4, 2026.
Key moments in the Lindsay Clancy case: the 911 call, mental health care, mistrial
The judge has declared a mistrial in the Lindsay Clancy murder trial.
Key moments in the Lindsay Clancy case: the 911 call, mental health care, mistrial
The judge has declared a mistrial in the Lindsay Clancy murder trial.
Key moments in the Lindsay Clancy case: the 911 call, mental health care, mistrial
The judge has declared a mistrial in the Lindsay Clancy murder trial. After seven days of deliberating, the jurors failed to reach a verdict on whether she was criminally responsible
Key moments in the Lindsay Clancy case: the 911 call, mental health care, mistrial
PLYMOUTH, Mass. (AP) — A mistrial was declared in the Lindsay Clancy murder trial on Friday after jurors failed to reach a verdict on whether she was
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
Andrea Yates attorney speaks on public views on women's mental health amid Lindsay Clancy trial
"I've seen changes in the way the public views women's mental health through the years," Andrea Yates's attorney said amid the Lindsay Clancy trial.
DeWitt breaks ground on detention ponds to support industrial development at Crossroads Business Park
The detention ponds are expected to be completed by the spring of 2027.
Prosecutors Won’t Try to Reinstate Key 9/11 Confession Taken After Torture
The military’s lawyers said they feared an appeal could delay the trial of the man accused of masterminding the attacks, which is scheduled to start in mid-2028.
Lindsay Clancy mistrial: 7 postpartum mental health takeaways
From extra privacy restrictions to medication trial and error, the case offered a rare window into coping with mental illness.
Start Your EA SPORTS NHL 27 Season Now With EA Play
Get a taste of life on the ice with the EA Play 10-hour early access trial of EA Sports NHL 27, available now.
Lindsay Clancy's case put a spotlight on parts of motherhood we don’t talk about
The case ended in a mistrial. But the frustrations raised by women around maternal mental health and racial inequities aren’t going away.
Two sectors are powering Ascension’s commercial property market
Retail and industrial properties kept Ascension Parish’s commercial real estate market on steady ground during the second quarter, even as the office sector continued to lag. The market recorded … Already an INSIDER? Sign in. Already an INSIDER? Sign in
BMW North America secures long-term lease in Wellford logistics park
Developed by Charleston-based Greystar, Mid85 is an industrial logistics park in Wellford adjacent to I-85 near the U.S. 29 interchange.
O.J. Simpson caught laughing about murder trial in behind-the-scenes clip from prank show
New docuseries about O.J. Simpson’s prank show ‘Juiced’ shows him laughing about his murder trial, which the crew hadn’t expected at all
One of the region's largest public companies completes $315M acquisition
Hillman Solutions expands into industrial fasteners with $315 million acquisition of Illinois-based Kanebridge Corp.
Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say
In the months before killing her children, Lindsay Clancy repeatedly sought help for her deteriorating mental health.